COCP Cocrystal Pharma, Inc.
Pharmaceutical Preparations · Nasdaq · SEC CIK 1412486 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY—
TTM net income YoY-17.2%
TTM EPS YoY18.3%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—
Margins
Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—
Returns
ROE-219.1%
ROA-131.6%
ROIC (approx.)—
Asset turnover—
Leverage & solvency
Liabilities / assets60.5%
Debt / equity0.00x
Current ratio1.72x
Interest coverage122.45x
Cash quality & payout
Operating cash flow / net income0.78x
Accruals ratio-28.4%
Payout ratio—
Capex / revenue—
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20252025-12-31 | FY20242024-12-31 | FY20232023-12-31 | FY20222022-12-31 | FY20212021-12-31 |
|---|---|---|---|---|---|
| Income statement | |||||
| Revenue | — | — | — | — | — |
| R&D expense | $5.05M | $12.54M | $15.17M | $12.39M | $8.79M |
| SG&A expense | $3.96M | $5.34M | $5.99M | $5.75M | $5.43M |
| Operating income | -$9.02M | -$17.88M | -$18.56M | -$38.83M | -$14.22M |
| Interest expense | -$134,000 | -$537,000 | -$640,000 | $2,000 | $4,000 |
| Pretax income | -$8.83M | -$18.63M | — | — | — |
| Net income | -$8.83M | -$17.50M | -$17.98M | -$38.84M | -$14.19M |
| EBITDA | -$8.95M | -$17.75M | -$18.37M | -$38.64M | -$14.03M |
| EPS (basic) | -0.78 | -1.72 | -1.87 | -4.77 | -0.16 |
| EPS (diluted) | -0.78 | -1.72 | -1.87 | -4.77 | -0.16 |
| Weighted avg. shares (diluted) | 11.29M | 10.17M | 9.65M | 8.14M | 88.37M |
| Balance sheet | |||||
| Cash & equivalents | $7.03M | $9.86M | $26.35M | $37.14M | $58.70M |
| Current assets | $8.13M | $11.58M | $29.09M | $40.18M | $59.32M |
| PP&E, net | $93,000 | $153,000 | $271,000 | $342,000 | $453,000 |
| Goodwill | — | — | — | — | $19.09M |
| Total assets | $9.71M | $13.46M | $31.26M | $40.84M | $79.39M |
| Current liabilities | $2.21M | $2.43M | $3.26M | $1.22M | $1.54M |
| Total liabilities | $3.38M | $3.93M | $4.88M | $1.27M | $1.84M |
| Shareholders' equity | $6.33M | $9.52M | $26.38M | $39.60M | $77.55M |
| Shares outstanding | 13.78M | 10.17M | 10.17M | 8.14M | 8.14M |
| Cash flow statement | |||||
| Operating cash flow | -$8.19M | -$16.48M | -$14.67M | -$21.43M | -$12.72M |
| Capital expenditure | $12,000 | $8,000 | $118,000 | $74,000 | $52,000 |
| Free cash flow | -$8.20M | -$16.49M | -$14.78M | -$21.51M | -$12.77M |
| Investing cash flow | -$12,000 | -$8,000 | -$118,000 | -$74,000 | -$52,000 |
| Financing cash flow | $5.37M | — | $3.99M | -$27,000 | $38.47M |
| Depreciation & amortization | $72,000 | $126,000 | $189,000 | $185,000 | $190,000 |
| Stock-based compensation | $270,000 | $643,000 | $801,000 | $855,000 | $724,000 |
Free plan shows the latest 5 periods; Pro shows all 16 🔒
· This company does not report gross profit in XBRL.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.